Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics].

Anna Wyszogrodzka-Kucharska1, Jolanta Rabe-Jabłońska

  • 1Centralny Szpital Kliniczny UM w Lodzi.

Psychiatria Polska
|March 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of white matter structure changes, as assessed in tractography, and cognitive dysfunctions in patients with early onset schizophrenia and their first-degree relatives.

Psychiatria polska·2017
Same author

Impact of lithium alone or in combination with haloperidol on oxidative stress parameters and cell viability in SH-SY5Y cell culture.

Acta neuropsychiatrica·2015
Same author

Impact of lithium alone or in combination with haloperidol on selected oxidative stress parameters in human plasma in vitro.

Redox report : communications in free radical research·2015
Same author

[Internal capsule integrity and its sex-related structural differences in early-onset schizophrenia - diffusion tensor imaging study].

Psychiatria polska·2015
Same author

Is there a decline in cognitive functions after combined electroconvulsive therapy and antipsychotic therapy in treatment-refractory schizophrenia?

The Journal of nervous and mental disease·2015
Same author

Augmentation of antipsychotics with electroconvulsive therapy in treatment-resistant schizophrenia patients with dominant negative symptoms: a pilot study of effectiveness.

Neuropsychobiology·2014

Patients with schizophrenia have lower bone mineral density (BMD) compared to healthy individuals. Early diagnosis and treatment can help reduce osteoporosis prevalence in this population.

Area of Science:

  • Bone Metabolism and Endocrinology
  • Psychiatric Pharmacotherapy
  • Public Health and Epidemiology

Background:

  • Decreased bone mineral density (BMD) can lead to osteopenia and osteoporosis.
  • In schizophrenia patients, BMD reduction is linked to hyperprolactinemia, hypogonadism, lifestyle factors (smoking, low activity, poor diet, low sun exposure), and polydipsia.
  • Many contributing factors to low BMD in schizophrenia are potentially modifiable.

Purpose of the Study:

  • To assess bone mineral density (BMD) in schizophrenia patients on second-generation antipsychotics.
  • To compare BMD in medicated schizophrenia patients against a control group of healthy, non-medicated volunteers.

Main Methods:

  • A study involving 60 schizophrenia patients (26 on risperidone, 34 on olanzapine) and 38 healthy controls.

Related Experiment Videos

  • Exclusion criteria targeted medical conditions or treatments known to affect bone density.
  • Bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry (DEXA) in premenopausal females.

    • Main Results:

    • Schizophrenia patients exhibited significantly lower mean bone mineral density (BMD) than the control group.
    • BMD was reduced in 37.7% of patients (28.3% osteopenia, 9.4% osteoporosis) versus 15.8% of controls (13.2% osteopenia, 2.6% osteoporosis).
    • No statistically significant BMD difference was observed between patients treated with risperidone or olanzapine.

    Conclusions:

    • Schizophrenia patients demonstrate lower bone mineral density (BMD) compared to healthy individuals.
    • The specific antipsychotics (risperidone or olanzapine) did not show differential effects on BMD in this study.
    • Early detection and intervention strategies are crucial to mitigate osteoporosis risk in schizophrenia.